Which has preferable valuation and earnings, LUNG or RXST?

RxSight has higher revenue and earnings than Pulmonx. RxSight is trading at a lower price-to-earnings ratio than Pulmonx, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Pulmonx $90.50M 0.69 -$54M -$1.30 N/A RxSight $134.48M 1.51 -$38.94M -$1.13 N/A

Is LUNG or RXST more profitable?

RxSight has a net margin of -36.58% compared to Pulmonx's net margin of -60.09%. RxSight's return on equity of -17.01% beat Pulmonx's return on equity. Company Net Margins Return on Equity Return on Assets Pulmonx -60.09% -92.94% -39.80% RxSight -36.58% -17.01% -15.12%

Which has preferable earnings and valuation, LUNG or SMTI?

Sanara MedTech has higher revenue and earnings than Pulmonx. Sanara MedTech is trading at a lower price-to-earnings ratio than Pulmonx, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Pulmonx $90.50M 0.69 -$54M -$1.30 N/A Sanara MedTech $103.12M 2.08 -$37.56M -$3.77 N/A

Is LUNG or SMTI more profitable?

Sanara MedTech has a net margin of -31.23% compared to Pulmonx's net margin of -60.09%. Sanara MedTech's return on equity of -3.19% beat Pulmonx's return on equity. Company Net Margins Return on Equity Return on Assets Pulmonx -60.09% -92.94% -39.80% Sanara MedTech -31.23% -3.19% -0.56%

Is LUNG or LUCD more profitable?

Pulmonx has a net margin of -60.09% compared to Lucid Diagnostics' net margin of -876.72%. Lucid Diagnostics' return on equity of 0.00% beat Pulmonx's return on equity. Company Net Margins Return on Equity Return on Assets Pulmonx -60.09% -92.94% -39.80% Lucid Diagnostics -876.72% N/A -116.26%

Which has preferable earnings and valuation, LUNG or INFU?

InfuSystem has higher revenue and earnings than Pulmonx. Pulmonx is trading at a lower price-to-earnings ratio than InfuSystem, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Pulmonx $90.50M 0.69 -$54M -$1.30 N/A InfuSystem $142.40M 1.30 $870K $0.38 24.18

Is LUNG or INFU more profitable?

InfuSystem has a net margin of 1.12% compared to Pulmonx's net margin of -60.09%. InfuSystem's return on equity of 2.78% beat Pulmonx's return on equity. Company Net Margins Return on Equity Return on Assets Pulmonx -60.09% -92.94% -39.80% InfuSystem 1.12% 2.78% 1.41%

Pulmonx (LUNG) Competitors

$1.48 +0.02 (+1.37%)

Closing price 04:00 PM Eastern

Extended Trading

$1.50 +0.02 (+1.69%)

As of 06:53 PM Eastern

Compare

LUNG vs. RXST, SMTI, LUCD, KRMD, and INFU

Should you buy Pulmonx stock or one of its competitors? MarketBeat compares Pulmonx with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Pulmonx include RxSight (RXST), Sanara MedTech (SMTI), Lucid Diagnostics (LUCD), KORU Medical Systems (KRMD), and InfuSystem (INFU). These companies are all part of the "medical equipment" industry.

How does Pulmonx compare to RxSight?

Pulmonx (NASDAQ:LUNG) and RxSight (NASDAQ:RXST) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, media sentiment, valuation, earnings, institutional ownership and dividends.

RxSight has higher revenue and earnings than Pulmonx. RxSight is trading at a lower price-to-earnings ratio than Pulmonx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pulmonx	$90.50M	0.69	-$54M	-$1.30	N/A
RxSight	$134.48M	1.51	-$38.94M	-$1.13	N/A

In the previous week, RxSight had 6 more articles in the media than Pulmonx. MarketBeat recorded 8 mentions for RxSight and 2 mentions for Pulmonx. Pulmonx's average media sentiment score of 1.17 beat RxSight's score of 0.35 indicating that Pulmonx is being referred to more favorably in the media.

Company	Overall Sentiment
Pulmonx	Positive
RxSight	Neutral

RxSight has a net margin of -36.58% compared to Pulmonx's net margin of -60.09%. RxSight's return on equity of -17.01% beat Pulmonx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pulmonx	-60.09%	-92.94%	-39.80%
RxSight	-36.58%	-17.01%	-15.12%

Pulmonx has a beta of 0.3, suggesting that its share price is 70% less volatile than the broader market. Comparatively, RxSight has a beta of 1.15, suggesting that its share price is 15% more volatile than the broader market.

Pulmonx currently has a consensus target price of $5.58, indicating a potential upside of 277.25%. RxSight has a consensus target price of $8.89, indicating a potential upside of 80.67%. Given Pulmonx's stronger consensus rating and higher possible upside, analysts plainly believe Pulmonx is more favorable than RxSight.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pulmonx	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
RxSight	3 Sell rating(s)	7 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.92

91.0% of Pulmonx shares are owned by institutional investors. Comparatively, 78.8% of RxSight shares are owned by institutional investors. 7.5% of Pulmonx shares are owned by insiders. Comparatively, 10.1% of RxSight shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

RxSight beats Pulmonx on 10 of the 16 factors compared between the two stocks.

How does Pulmonx compare to Sanara MedTech?

Pulmonx (NASDAQ:LUNG) and Sanara MedTech (NASDAQ:SMTI) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, risk, earnings, valuation, media sentiment, profitability, analyst recommendations and dividends.

In the previous week, Pulmonx and Pulmonx both had 2 articles in the media. Sanara MedTech's average media sentiment score of 1.45 beat Pulmonx's score of 1.17 indicating that Sanara MedTech is being referred to more favorably in the news media.

Company	Overall Sentiment
Pulmonx	Positive
Sanara MedTech	Positive

91.0% of Pulmonx shares are held by institutional investors. Comparatively, 8.1% of Sanara MedTech shares are held by institutional investors. 7.5% of Pulmonx shares are held by insiders. Comparatively, 42.0% of Sanara MedTech shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Sanara MedTech has a net margin of -31.23% compared to Pulmonx's net margin of -60.09%. Sanara MedTech's return on equity of -3.19% beat Pulmonx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pulmonx	-60.09%	-92.94%	-39.80%
Sanara MedTech	-31.23%	-3.19%	-0.56%

Pulmonx has a beta of 0.3, meaning that its share price is 70% less volatile than the broader market. Comparatively, Sanara MedTech has a beta of 1.18, meaning that its share price is 18% more volatile than the broader market.

Pulmonx currently has a consensus price target of $5.58, indicating a potential upside of 277.25%. Sanara MedTech has a consensus price target of $34.00, indicating a potential upside of 44.99%. Given Pulmonx's higher probable upside, analysts plainly believe Pulmonx is more favorable than Sanara MedTech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pulmonx	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Sanara MedTech	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60

Sanara MedTech has higher revenue and earnings than Pulmonx. Sanara MedTech is trading at a lower price-to-earnings ratio than Pulmonx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pulmonx	$90.50M	0.69	-$54M	-$1.30	N/A
Sanara MedTech	$103.12M	2.08	-$37.56M	-$3.77	N/A

Summary

Sanara MedTech beats Pulmonx on 11 of the 16 factors compared between the two stocks.

How does Pulmonx compare to Lucid Diagnostics?

Pulmonx (NASDAQ:LUNG) and Lucid Diagnostics (NASDAQ:LUCD) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, analyst recommendations, profitability, dividends and earnings.

Pulmonx has a beta of 0.3, suggesting that its share price is 70% less volatile than the broader market. Comparatively, Lucid Diagnostics has a beta of 1.07, suggesting that its share price is 7% more volatile than the broader market.

91.0% of Pulmonx shares are held by institutional investors. Comparatively, 74.0% of Lucid Diagnostics shares are held by institutional investors. 7.5% of Pulmonx shares are held by company insiders. Comparatively, 6.9% of Lucid Diagnostics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Pulmonx has higher revenue and earnings than Lucid Diagnostics. Lucid Diagnostics is trading at a lower price-to-earnings ratio than Pulmonx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pulmonx	$90.50M	0.69	-$54M	-$1.30	N/A
Lucid Diagnostics	$4.71M	43.11	-$58.01M	-$0.47	N/A

In the previous week, Pulmonx had 1 more articles in the media than Lucid Diagnostics. MarketBeat recorded 2 mentions for Pulmonx and 1 mentions for Lucid Diagnostics. Lucid Diagnostics' average media sentiment score of 1.87 beat Pulmonx's score of 1.17 indicating that Lucid Diagnostics is being referred to more favorably in the news media.

Company	Overall Sentiment
Pulmonx	Positive
Lucid Diagnostics	Very Positive

Pulmonx presently has a consensus target price of $5.58, suggesting a potential upside of 277.25%. Lucid Diagnostics has a consensus target price of $4.19, suggesting a potential upside of 318.75%. Given Lucid Diagnostics' stronger consensus rating and higher probable upside, analysts clearly believe Lucid Diagnostics is more favorable than Pulmonx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pulmonx	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Lucid Diagnostics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

Pulmonx has a net margin of -60.09% compared to Lucid Diagnostics' net margin of -876.72%. Lucid Diagnostics' return on equity of 0.00% beat Pulmonx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pulmonx	-60.09%	-92.94%	-39.80%
Lucid Diagnostics	-876.72%	N/A	-116.26%

Summary

Pulmonx beats Lucid Diagnostics on 8 of the 15 factors compared between the two stocks.

How does Pulmonx compare to KORU Medical Systems?

Pulmonx (NASDAQ:LUNG) and KORU Medical Systems (NASDAQ:KRMD) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, institutional ownership, dividends, analyst recommendations, valuation, media sentiment, profitability and earnings.

Pulmonx currently has a consensus price target of $5.58, suggesting a potential upside of 277.25%. KORU Medical Systems has a consensus price target of $7.25, suggesting a potential upside of 74.70%. Given Pulmonx's higher possible upside, equities research analysts plainly believe Pulmonx is more favorable than KORU Medical Systems.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pulmonx	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
KORU Medical Systems	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

KORU Medical Systems has lower revenue, but higher earnings than Pulmonx. KORU Medical Systems is trading at a lower price-to-earnings ratio than Pulmonx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pulmonx	$90.50M	0.69	-$54M	-$1.30	N/A
KORU Medical Systems	$41.13M	4.63	-$2.64M	-$0.05	N/A

In the previous week, KORU Medical Systems had 1 more articles in the media than Pulmonx. MarketBeat recorded 3 mentions for KORU Medical Systems and 2 mentions for Pulmonx. Pulmonx's average media sentiment score of 1.17 beat KORU Medical Systems' score of 0.62 indicating that Pulmonx is being referred to more favorably in the media.

Company	Overall Sentiment
Pulmonx	Positive
KORU Medical Systems	Positive

Pulmonx has a beta of 0.3, suggesting that its share price is 70% less volatile than the broader market. Comparatively, KORU Medical Systems has a beta of 0.41, suggesting that its share price is 59% less volatile than the broader market.

91.0% of Pulmonx shares are held by institutional investors. Comparatively, 58.6% of KORU Medical Systems shares are held by institutional investors. 7.5% of Pulmonx shares are held by insiders. Comparatively, 18.5% of KORU Medical Systems shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

KORU Medical Systems has a net margin of -5.27% compared to Pulmonx's net margin of -60.09%. KORU Medical Systems' return on equity of -13.61% beat Pulmonx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pulmonx	-60.09%	-92.94%	-39.80%
KORU Medical Systems	-5.27%	-13.61%	-8.33%

Summary

KORU Medical Systems beats Pulmonx on 10 of the 15 factors compared between the two stocks.

How does Pulmonx compare to InfuSystem?

Pulmonx (NASDAQ:LUNG) and InfuSystem (NYSE:INFU) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, earnings, profitability, valuation, risk, media sentiment, analyst recommendations and institutional ownership.

InfuSystem has a net margin of 1.12% compared to Pulmonx's net margin of -60.09%. InfuSystem's return on equity of 2.78% beat Pulmonx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pulmonx	-60.09%	-92.94%	-39.80%
InfuSystem	1.12%	2.78%	1.41%

InfuSystem has higher revenue and earnings than Pulmonx. Pulmonx is trading at a lower price-to-earnings ratio than InfuSystem, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pulmonx	$90.50M	0.69	-$54M	-$1.30	N/A
InfuSystem	$142.40M	1.30	$870K	$0.38	24.18

Pulmonx has a beta of 0.3, meaning that its share price is 70% less volatile than the broader market. Comparatively, InfuSystem has a beta of 1.4, meaning that its share price is 40% more volatile than the broader market.

Pulmonx currently has a consensus price target of $5.58, indicating a potential upside of 277.25%. InfuSystem has a consensus price target of $15.00, indicating a potential upside of 63.22%. Given Pulmonx's higher probable upside, research analysts clearly believe Pulmonx is more favorable than InfuSystem.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pulmonx	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
InfuSystem	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67

91.0% of Pulmonx shares are owned by institutional investors. Comparatively, 71.1% of InfuSystem shares are owned by institutional investors. 7.5% of Pulmonx shares are owned by company insiders. Comparatively, 10.8% of InfuSystem shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Pulmonx had 2 more articles in the media than InfuSystem. MarketBeat recorded 2 mentions for Pulmonx and 0 mentions for InfuSystem. Pulmonx's average media sentiment score of 1.17 beat InfuSystem's score of 0.00 indicating that Pulmonx is being referred to more favorably in the media.

Company	Overall Sentiment
Pulmonx	Positive
InfuSystem	Neutral

Summary

InfuSystem beats Pulmonx on 11 of the 16 factors compared between the two stocks.

Get Pulmonx News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LUNG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LUNG vs. The Competition

Export

Metric	Pulmonx	MEDICAL INFO SYS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$61.67M	$1.84B	$6.85B	$12.45B
Dividend Yield	N/A	N/A	2.68%	8.43%
P/E Ratio	-1.14	76.84	27.04	24.38
Price / Sales	0.69	7.74	524.25	93.51
Price / Cash	N/A	27.73	48.59	59.36
Price / Book	1.13	5.60	10.80	6.33
Net Income	-$54M	-$54.76M	$3.59B	$331.02M
7 Day Performance	-3.27%	-2.64%	-2.24%	-1.09%
1 Month Performance	8.03%	4.87%	3.12%	-0.49%
1 Year Performance	-44.78%	-0.49%	26.30%	19.90%

Pulmonx Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LUNG Pulmonx	3.2222 of 5 stars	$1.48 +1.4%	$5.58 +277.3%	-49.7%	$61.67M	$90.50M	N/A	250	Positive News Short Interest Decrease
RXST RxSight	2.6488 of 5 stars	$5.60 -0.2%	$9.44 +68.7%	-36.8%	$232.24M	$134.48M	N/A	220	Analyst Upgrade
SMTI Sanara MedTech	2.4194 of 5 stars	$25.17 +1.3%	$34.00 +35.1%	-14.2%	$227.63M	$103.12M	N/A	60	News Coverage
LUCD Lucid Diagnostics	4.1615 of 5 stars	$1.08 +0.9%	$4.19 +287.7%	-13.1%	$217.28M	$4.71M	N/A	70	Positive News
KRMD KORU Medical Systems	4.2704 of 5 stars	$4.60 +2.4%	$7.25 +57.6%	+21.6%	$206.24M	$41.13M	N/A	80

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LUNG) was last updated on 7/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Pulmonx (LUNG) Competitors

LUNG vs. RXST, SMTI, LUCD, KRMD, and INFU

How does Pulmonx compare to RxSight?

Summary

How does Pulmonx compare to Sanara MedTech?

Summary

How does Pulmonx compare to Lucid Diagnostics?

Summary

How does Pulmonx compare to KORU Medical Systems?

Summary

How does Pulmonx compare to InfuSystem?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LUNG vs. The Competition

Pulmonx Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Pulmonx (LUNG) Competitors

LUNG vs. RXST, SMTI, LUCD, KRMD, and INFU

How does Pulmonx compare to RxSight?

Which has preferable valuation and earnings, LUNG or RXST?

Does the media refer more to LUNG or RXST?

Is LUNG or RXST more profitable?

Which has more volatility & risk, LUNG or RXST?

Do analysts prefer LUNG or RXST?

Do insiders & institutionals have more ownership in LUNG or RXST?

Summary

How does Pulmonx compare to Sanara MedTech?

Does the media favor LUNG or SMTI?

Do insiders and institutionals have more ownership in LUNG or SMTI?

Is LUNG or SMTI more profitable?

Which has more risk & volatility, LUNG or SMTI?

Do analysts recommend LUNG or SMTI?

Which has preferable earnings and valuation, LUNG or SMTI?

Summary

How does Pulmonx compare to Lucid Diagnostics?

Which has more risk & volatility, LUNG or LUCD?

Do insiders & institutionals believe in LUNG or LUCD?

Which has better earnings & valuation, LUNG or LUCD?

Does the media refer more to LUNG or LUCD?

Do analysts prefer LUNG or LUCD?

Is LUNG or LUCD more profitable?

Summary

How does Pulmonx compare to KORU Medical Systems?

Do analysts rate LUNG or KRMD?

Which has preferable valuation & earnings, LUNG or KRMD?

Does the media refer more to LUNG or KRMD?

Which has more volatility & risk, LUNG or KRMD?

Do insiders and institutionals believe in LUNG or KRMD?

Is LUNG or KRMD more profitable?

Summary

How does Pulmonx compare to InfuSystem?

Is LUNG or INFU more profitable?

Which has preferable earnings and valuation, LUNG or INFU?

Which has more risk and volatility, LUNG or INFU?

Do analysts recommend LUNG or INFU?

Do insiders & institutionals have more ownership in LUNG or INFU?

Does the media refer more to LUNG or INFU?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LUNG vs. The Competition

Pulmonx Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools